The HIV+Hepatitis Policy Institute, a non-profit organization, is very grateful for support from individuals, foundations, and corporations that invest in our mission to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. The HIV and Hepatitis Policy Institute is a 501(c)(3) tax-exempt organization. Donations to HIV+Hep are tax-deductible to the full extent allowed by law.
If you are interested in making a donation, please contact: Carl Schmid, Executive Director, at cschmid@hivhep.org.
1602B Belmont Street NW | Washington DC 20009
Facebook posts by @HIV+Hep
We continue to advocate for lower #outofpocket costs to #patients in comments to the Maryland Prescription #drug Affordability Stakeholder Council as it considers which drugs to review: bit.ly/4aQnPCB
Despite our lawsuit against HHS.Gov, which we won, Secretary Becerra doesn’t understand how insurers & #PBMs aren’t counting #copayassistance dollars towards #outofpocket costs. He thinks there is no harm to #Rx access & confuses it w/Medicare. Watch exchange w/Congressman Buddy Carter:
Our HIV policy and advocacy work must plan for the future.
Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatment (Gift Article)
www.nytimes.com
New regimens in development, including once-weekly pills and semiannual shots, could help control the virus in hard-to-reach populations.
We are grateful to Congressman Buddy Carter for asking Secretary Becerra why the administration isn’t allowing copays to count. “The D.C. District Court struck down the rule that allows #insurers to implement these harmful progs, but your dept is defying that decision & has gone on record saying you will not enforce the court decision. Why are you defying the court’s decision? When will you issue a new rule clarifying that ALL #costsharing counts for #patients to meet their deductibles?”
From @AISHealth: “With the regulations governing #copayaccumulators still in flux, Carl Schmid says #patients continue to contact the HIV and Hepatitis Policy Institute to complain that they’re getting ‘huge bills [they] didn’t expect’ because of their pharma-provided #copayassistance not counting toward their #costsharing obligations. ‘That’s why we’re looking at future legal action that patients can take’”:
Advocates’ Frustration Mounts Amid CMS Inaction on Copay Accumulators
bit.ly
Language stating CMS will enforce a court ruling regarding the use of copay accumulator programs is missing from a new regulation.